Sana Biotech's HIP-modified islets show durable function at 14 months

Sana Biotechnology has announced publication of a peer-reviewed Letter to the Editor in The New England Journal of Medicine, reporting 14-month follow-up data from an investigator-sponsored study of UP421, an allogeneic primary human pancreatic islet cell therapy engineered with the company's hypoimmune (HIP) platform technology. The data show transplanted beta cells continuing to survive and produce insulin in a patient with type 1 diabetes, with no requirement for immunosuppression.

The study, conducted at Uppsala University Hospital and supported by a grant from the Helmsley Charitable Trust, is a first-in-human evaluation of HIP-modified primary islet cells transplanted intramuscularly into the forearm. At 14 months, circulating C-peptide levels remained detectable both fasting and during a mixed meal tolerance test, indicating continued endogenous insulin secretion. PET-MRI scanning confirmed the presence of islet cells at the transplant site. The patient had undetectable C-peptide at baseline, and no safety concerns have been identified.

Per-Ola Carlsson, Professor at Uppsala University Hospital's Clinic for Endocrinology and Diabetology and the study's principal investigator, said: "After a century of relying on insulin, people living with type 1 diabetes deserve more than incremental improvements. With this 14-month follow-up data using the hypoimmune technology, we believe that a functional cure for type 1 diabetes without immunosuppression is possible."

Towards the clinic: SC451

Sana is positioning the UP421 findings as supporting evidence for its proprietary product candidate SC451, a stem cell-derived, HIP-modified pancreatic islet therapy intended as a scalable, one-time treatment. Unlike the donor-derived primary cells used in UP421, SC451 is manufactured from gene-modified stem cells, which the company says could allow broader patient access. Sana said it expects to file an Investigational New Drug application with the FDA and initiate a Phase 1/2 trial for SC451 as early as this year.

The HIP technology is designed to confer dual immune evasion: resistance to both allogeneic rejection (from unmatched donor cells) and the autoimmune attack that underlies type 1 diabetes itself. If the mechanism holds in larger, more diverse cohorts, it could remove the principal barrier to widespread use of cell replacement therapies, namely the lifelong immunosuppression regimens that currently limit islet transplantation to patients with severe, unstable disease.

Market and competitive context

The type 1 diabetes cell therapy field has grown considerably in the past two years, anchored by the FDA approval of Vertex Pharmaceuticals' VX-880 programme and the broader interest in stem cell-derived islet approaches. The central question for the sector is whether immune evasion can be engineered rather than managed pharmacologically. Sana is one of a small number of companies pursuing hypoimmune modification as a solution, and the NEJM publications lend the programme a degree of clinical credibility that peer-reviewed conference abstracts cannot replicate.

The current data come from a low-dose, single-patient study not powered to demonstrate glycaemic improvement or reduction in exogenous insulin use. Investors and clinicians will look to the Phase 1/2 SC451 trial for evidence that the effect scales to a therapeutic dose in a broader patient population, and for comparative data on C-peptide trajectories relative to competing approaches. The IND filing timeline, if maintained, would make 2026 a pivotal year for Sana's diabetes franchise.